Improving Outcomes for Patients Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy

Explore expert insights on the optimal utilization of HER2-targeted ADCs in patients with advanced NSCLC in an on-demand webcast derived from a live event. Then, download the accompanying slides for a comprehensive reference on the latest advancements in treatment strategies.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.